JP2011092201A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011092201A5 JP2011092201A5 JP2010286755A JP2010286755A JP2011092201A5 JP 2011092201 A5 JP2011092201 A5 JP 2011092201A5 JP 2010286755 A JP2010286755 A JP 2010286755A JP 2010286755 A JP2010286755 A JP 2010286755A JP 2011092201 A5 JP2011092201 A5 JP 2011092201A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- compound
- oligonucleotide
- inhibiting
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 108091034117 Oligonucleotide Proteins 0.000 claims 8
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 108010017842 Telomerase Proteins 0.000 claims 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims 3
- 229930195729 fatty acid Natural products 0.000 claims 3
- 239000000194 fatty acid Substances 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000005907 cancer growth Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50150903P | 2003-09-09 | 2003-09-09 | |
| US60/501,509 | 2003-09-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006526347A Division JP4690324B2 (ja) | 2003-09-09 | 2004-09-09 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011274595A Division JP2012085648A (ja) | 2003-09-09 | 2011-12-15 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2014087190A Division JP2014158490A (ja) | 2003-09-09 | 2014-04-21 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2016014128A Division JP6158966B2 (ja) | 2003-09-09 | 2016-01-28 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011092201A JP2011092201A (ja) | 2011-05-12 |
| JP2011092201A5 true JP2011092201A5 (https=) | 2012-02-16 |
| JP5923241B2 JP5923241B2 (ja) | 2016-05-24 |
Family
ID=34273050
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006526347A Expired - Lifetime JP4690324B2 (ja) | 2003-09-09 | 2004-09-09 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2010286755A Expired - Lifetime JP5923241B2 (ja) | 2003-09-09 | 2010-12-22 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2011274595A Pending JP2012085648A (ja) | 2003-09-09 | 2011-12-15 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2014087190A Pending JP2014158490A (ja) | 2003-09-09 | 2014-04-21 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2016014128A Expired - Lifetime JP6158966B2 (ja) | 2003-09-09 | 2016-01-28 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2016137263A Withdrawn JP2016214248A (ja) | 2003-09-09 | 2016-07-12 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2018025362A Expired - Lifetime JP6758335B2 (ja) | 2003-09-09 | 2018-02-15 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2019131757A Withdrawn JP2019170400A (ja) | 2003-09-09 | 2019-07-17 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2021110558A Withdrawn JP2021169466A (ja) | 2003-09-09 | 2021-07-02 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2023086871A Withdrawn JP2023099808A (ja) | 2003-09-09 | 2023-05-26 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006526347A Expired - Lifetime JP4690324B2 (ja) | 2003-09-09 | 2004-09-09 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011274595A Pending JP2012085648A (ja) | 2003-09-09 | 2011-12-15 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2014087190A Pending JP2014158490A (ja) | 2003-09-09 | 2014-04-21 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2016014128A Expired - Lifetime JP6158966B2 (ja) | 2003-09-09 | 2016-01-28 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2016137263A Withdrawn JP2016214248A (ja) | 2003-09-09 | 2016-07-12 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2018025362A Expired - Lifetime JP6758335B2 (ja) | 2003-09-09 | 2018-02-15 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2019131757A Withdrawn JP2019170400A (ja) | 2003-09-09 | 2019-07-17 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2021110558A Withdrawn JP2021169466A (ja) | 2003-09-09 | 2021-07-02 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP2023086871A Withdrawn JP2023099808A (ja) | 2003-09-09 | 2023-05-26 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
Country Status (19)
| Country | Link |
|---|---|
| US (8) | US7494982B2 (https=) |
| EP (3) | EP3342425B1 (https=) |
| JP (10) | JP4690324B2 (https=) |
| KR (3) | KR101319388B1 (https=) |
| CN (2) | CN100393209C (https=) |
| AU (2) | AU2004271215B2 (https=) |
| BR (1) | BRPI0414222B8 (https=) |
| CA (1) | CA2536015C (https=) |
| CY (2) | CY1120113T1 (https=) |
| DK (2) | DK1667522T3 (https=) |
| ES (2) | ES2662196T3 (https=) |
| HU (2) | HUE036593T2 (https=) |
| IL (1) | IL173747A (https=) |
| MX (1) | MXPA06002660A (https=) |
| NZ (1) | NZ545516A (https=) |
| PL (2) | PL1667522T3 (https=) |
| PT (2) | PT3342425T (https=) |
| SI (2) | SI3342425T1 (https=) |
| WO (1) | WO2005023994A2 (https=) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1667522T3 (pl) | 2003-09-09 | 2018-06-29 | Geron Corporation | Zmodyfikowane oligonukleotydy do hamowania telomerazy |
| DE602004031975D1 (de) * | 2003-11-04 | 2011-05-05 | Geron Corp | Rna-amidate und thioamidateur rnai |
| HRP20171705T1 (hr) | 2004-07-02 | 2017-12-15 | Geron Corporation | Sinteza zaštićenih 3’-amino-nukleozidnih monomera |
| WO2006113470A2 (en) * | 2005-04-15 | 2006-10-26 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
| WO2006138145A1 (en) | 2005-06-14 | 2006-12-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
| US8153604B2 (en) * | 2006-04-24 | 2012-04-10 | Geron Corporation | CNS-tumor treatment method and composition |
| LT2898887T (lt) * | 2006-10-30 | 2018-11-12 | Geron Corporation | Telomerazės inhibitoriaus ir gemcitabino derinys vėžio gydymui |
| US8785409B2 (en) | 2007-01-30 | 2014-07-22 | Geron Corporation | Compounds having anti-adhesive effects on cancer cells |
| EP2121987B1 (en) | 2007-02-09 | 2012-06-13 | Northwestern University | Particles for detecting intracellular targets |
| EP2134364B1 (en) * | 2007-03-09 | 2013-02-13 | Geron Corporation | Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors |
| DK2476689T3 (en) | 2007-05-10 | 2016-01-18 | Agilent Technologies Inc | Thiocarbonbeskyttende groups for RNA synthesis |
| EP2160464B1 (en) | 2007-05-30 | 2014-05-21 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
| TW200927177A (en) * | 2007-10-24 | 2009-07-01 | Nat Inst Of Advanced Ind Scien | Lipid-modified double-stranded RNA having potent RNA interference effect |
| AU2009265194A1 (en) * | 2008-07-02 | 2010-01-07 | Enzon Pharmaceuticals Inc | RNA antagonists targeting Hsp27 |
| EP2175023A1 (en) * | 2008-07-31 | 2010-04-14 | The University of Zurich | Anti-tumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA |
| EP3029154B1 (en) | 2008-10-17 | 2017-10-04 | Geron Corporation | Method for identification of sensitivity of a patient to telomerase inhibition therapy |
| EP2365803B1 (en) | 2008-11-24 | 2017-11-01 | Northwestern University | Polyvalent rna-nanoparticle compositions |
| CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| RU2612521C2 (ru) | 2009-07-06 | 2017-03-09 | Онтории, Инк. | Новые пролекарства нуклеиновых кислот и способы их применения |
| CA2779099C (en) | 2009-10-30 | 2021-08-10 | Northwestern University | Templated nanoconjugates |
| WO2011079290A1 (en) * | 2009-12-24 | 2011-06-30 | Northwestern University | Oligonucleotide specific uptake of nanoconjugates |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| ES2656958T3 (es) | 2011-03-28 | 2018-03-01 | Geron Corporation | Medición de la longitud de telómeros en muestras fijadas en formalina, embebidas en parafina (FFPE) por PCR cuantitativa |
| CN103796657B (zh) | 2011-07-19 | 2017-07-11 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| AU2012308302A1 (en) | 2011-09-14 | 2014-03-20 | Northwestern University | Nanoconjugates able to cross the blood-brain barrier |
| KR102213609B1 (ko) | 2012-07-13 | 2021-02-08 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| PL2872485T3 (pl) | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymetryczna grupa pomocnicza |
| CA3201145A1 (en) | 2012-10-26 | 2014-05-01 | Geron Corporation | C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders |
| US9228189B2 (en) | 2012-10-26 | 2016-01-05 | Geron Corporation | C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders |
| JP6359028B2 (ja) | 2012-11-30 | 2018-07-18 | ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ | テロメラーゼ阻害剤を用いて細胞増殖性障害を処置するための診断マーカー |
| US9200327B2 (en) | 2012-11-30 | 2015-12-01 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
| US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| RS59363B1 (sr) | 2012-12-07 | 2019-11-29 | Geron Corp | Upotreba inhibitora telomeraze imetelstata za lečenje mijelofibroze |
| AU2014218667A1 (en) | 2013-02-22 | 2015-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds, compositions, methods, and kits relating to telomere extension |
| EP3024936B1 (en) | 2013-07-25 | 2019-09-04 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| US9708360B2 (en) | 2013-09-30 | 2017-07-18 | Geron Corporation | Phosphorodiamidate backbone linkage for oligonucleotides |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| BR112016016400A2 (pt) | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
| JOP20200257A1 (ar) | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
| TR201908550T4 (tr) | 2014-06-04 | 2019-07-22 | Exicure Inc | Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi. |
| US11213593B2 (en) | 2014-11-21 | 2022-01-04 | Northwestern University | Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| KR101766373B1 (ko) * | 2015-01-05 | 2017-08-09 | 권영아 | 루테리온을 이용한 암세포의 텔로머라아제 억제방법 |
| MA42157A (fr) * | 2015-04-23 | 2018-02-28 | Geron Corp | Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent |
| EP3124609A1 (en) | 2015-07-29 | 2017-02-01 | IFOM Fondazione Istituto Firc di Oncologia Molecolare | Therapeutics oligonucleotides |
| ES2781459T3 (es) | 2015-07-29 | 2020-09-02 | Ifom Fondazione St Firc Di Oncologia Molecolare | Oligonucleótidos terapéuticos |
| CN109462995A (zh) * | 2016-05-04 | 2019-03-12 | 波涛生命科学有限公司 | 生物活性剂的方法和组合物 |
| EP3318276A1 (en) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
| EP4036101A1 (en) * | 2017-04-20 | 2022-08-03 | Synthena AG | Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof |
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| CA3195922A1 (en) * | 2017-07-10 | 2019-01-17 | Geron Corporation | Improved process for preparing imetelstat |
| JP7316261B2 (ja) | 2017-07-28 | 2023-07-27 | ジェロン・コーポレーション | 骨髄異形成症候群の治療方法 |
| MX2020011570A (es) | 2018-05-07 | 2020-11-24 | Alnylam Pharmaceuticals Inc | Administracion extrahepatica. |
| KR20250074692A (ko) | 2018-11-29 | 2025-05-27 | 제론 코포레이션 | 골수이형성 증후군을 치료하는 방법 |
| WO2021054370A1 (ja) * | 2019-09-18 | 2021-03-25 | 国立大学法人東京医科歯科大学 | 核酸複合体 |
| IL292328B2 (en) | 2019-10-28 | 2025-10-01 | Geron Corp | Succinylate-converted 3-(amido fatty acid)-2-hydroxy-1-(protected hydroxy)-propane salts, amorphous solids and methods for their preparation |
| EP4051252A4 (en) | 2019-10-28 | 2023-12-06 | Geron Corporation | CRYSTALLINE SOLIDS OF 3-PALMITOYL-AMIDO -1,2-PROPANEDIOL AND 3-PALMITOYL-AMIDO-2-HYDROXY-1-DIMETHOXYTRIPHENYLMETHYL ETHER-PROPANE AND METHODS OF MANUFACTURE AND USE THEREOF |
| IL299205A (en) | 2020-07-17 | 2023-02-01 | Geron Corp | Subcutaneous telomerase inhibitor preparations and methods of using them |
| WO2022186350A1 (ja) * | 2021-03-03 | 2022-09-09 | 国立大学法人東京大学 | 非環式スレオニノール核酸 |
| EP4316495A4 (en) * | 2021-03-25 | 2025-12-31 | Aptacure Therapeutics Ltd | CONJUGATE OF NUCLEIC ACID MOLECULE HAVING A PROLONGED IN VIVO HALF-LIFE |
| EP4463151A4 (en) | 2022-01-19 | 2025-10-01 | Univ Northwestern | Agents Targeting Telomerase Reverse Transcriptase (TERT) to Treat Cancer and Sensitize Cancer Cells to Genotoxic Therapy |
| WO2024257861A1 (ja) * | 2023-06-16 | 2024-12-19 | 日産化学株式会社 | 脂質結合オリゴヌクレオチド又はその複合体 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US4757141A (en) | 1985-08-26 | 1988-07-12 | Applied Biosystems, Incorporated | Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof |
| US4659774A (en) | 1985-11-01 | 1987-04-21 | American Hoechst Corporation | Support for solid-phase oligonucleotide synthesis |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| CA2049028A1 (en) * | 1989-03-07 | 1990-09-08 | Genentech, Inc. | Covalent conjugates of lipid and oligonucleotide |
| US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
| US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US6114513A (en) | 1990-01-11 | 2000-09-05 | Isis Pharmaceuticals, Inc. | Thiol-derivatized oligonucleotides |
| US6395492B1 (en) | 1990-01-11 | 2002-05-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| AU7759291A (en) * | 1990-03-29 | 1991-10-21 | Gilead Sciences, Inc. | Oligonucleotide-transport agent disulfide conjugates |
| US5420330A (en) | 1990-09-07 | 1995-05-30 | Pharmacia P-L Biochemicals Inc. | Lipo-phosphoramidites |
| US5419966A (en) * | 1991-06-10 | 1995-05-30 | Microprobe Corporation | Solid support for synthesis of 3'-tailed oligonucleotides |
| US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
| US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
| US5837453A (en) | 1992-05-13 | 1998-11-17 | Geron Corporation | Telomerase activity assays |
| US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
| US7067497B2 (en) * | 1992-09-29 | 2006-06-27 | Isis Pharmaceuticals, Inc. | Modulation of telomere length by oligonucleotides having a G-core sequence |
| US5523389A (en) | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
| US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
| US6350853B1 (en) | 1993-04-26 | 2002-02-26 | Peter E. Nielsen | Conjugated peptide nucleic acids having enhanced cellular uptake |
| DE4331670A1 (de) | 1993-09-17 | 1995-03-23 | Hoechst Ag | Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung |
| WO1995011253A1 (en) | 1993-10-18 | 1995-04-27 | The Walter And Eliza Hall Institute Of Medical Research | A method for enhancing neurone survival and agents useful for same |
| US5863726A (en) | 1993-11-12 | 1999-01-26 | Geron Corporation | Telomerase activity assays |
| CZ274596A3 (en) | 1994-03-18 | 1997-03-12 | Lynx Therapeutics | Oligonucleotide n3 - p5 phosphoramidates and process of their synthesis and hybridization |
| US5726297A (en) | 1994-03-18 | 1998-03-10 | Lynx Therapeutics, Inc. | Oligodeoxyribonucleotide N3' P5' phosphoramidates |
| US5599922A (en) | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
| GB9413035D0 (en) | 1994-06-29 | 1994-08-17 | Scras | Antisense oligonucleeotides |
| US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
| RO117328B1 (ro) | 1994-07-07 | 2002-01-30 | Geron Corp | Componenta rna a telomerazei de mamifere, plasmida recombinanta, de exprimare a acesteia, si metoda pentru detectarea prezentei unei stari neoplazice |
| US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
| CN1165508A (zh) | 1994-11-07 | 1997-11-19 | 海布里顿公司 | 利用3h-1,2-苯并二硫酚-3-1,1二氧化物合成35s-标记的寡核苷酸 |
| US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
| US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
| US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
| US5840490A (en) | 1995-06-07 | 1998-11-24 | Mcmaster University | Telomerase activity associated with hematological and colorectal malignancies |
| US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
| US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
| US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
| US5859233A (en) | 1996-02-21 | 1999-01-12 | Lynx Therapeutics, Inc. | Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates |
| GB9606158D0 (en) | 1996-03-23 | 1996-05-29 | Ciba Geigy Ag | Chemical compounds |
| US6015710A (en) * | 1996-04-09 | 2000-01-18 | The University Of Texas System | Modulation of mammalian telomerase by peptide nucleic acids |
| AU2445997A (en) * | 1996-04-10 | 1997-10-29 | Lynx Therapeutics, Inc. | Telomerase inhibitors |
| US6111085A (en) | 1996-09-13 | 2000-08-29 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
| US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| US6001991A (en) | 1996-10-04 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression |
| CA2274586A1 (en) | 1996-12-20 | 1998-07-02 | Geron Corporation | Methods for detecting and inhibiting the rna component of telomerase |
| US5846723A (en) | 1996-12-20 | 1998-12-08 | Geron Corporation | Methods for detecting the RNA component of telomerase |
| US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
| US5998604A (en) | 1997-09-15 | 1999-12-07 | The Perkin-Elmer Corporation | Polynucleotide purification method |
| JP3722630B2 (ja) | 1998-10-28 | 2005-11-30 | パイオニア株式会社 | 記録再生装置 |
| US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
| CN1317291C (zh) | 1999-09-10 | 2007-05-23 | 杰龙公司 | 寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用 |
| US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
| US7563618B2 (en) | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
| CA2440322C (en) | 2001-03-23 | 2014-09-09 | Geron Corporation | Oligonucleotide conjugates |
| US20120329858A1 (en) | 2010-08-04 | 2012-12-27 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
| PL1667522T3 (pl) | 2003-09-09 | 2018-06-29 | Geron Corporation | Zmodyfikowane oligonukleotydy do hamowania telomerazy |
| HRP20171705T1 (hr) | 2004-07-02 | 2017-12-15 | Geron Corporation | Sinteza zaštićenih 3’-amino-nukleozidnih monomera |
| WO2006113470A2 (en) | 2005-04-15 | 2006-10-26 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
| US8153604B2 (en) | 2006-04-24 | 2012-04-10 | Geron Corporation | CNS-tumor treatment method and composition |
| LT2898887T (lt) | 2006-10-30 | 2018-11-12 | Geron Corporation | Telomerazės inhibitoriaus ir gemcitabino derinys vėžio gydymui |
-
2004
- 2004-09-09 PL PL04783801T patent/PL1667522T3/pl unknown
- 2004-09-09 CN CNB2004800259754A patent/CN100393209C/zh not_active Expired - Lifetime
- 2004-09-09 SI SI200432487T patent/SI3342425T1/sl unknown
- 2004-09-09 DK DK04783801.6T patent/DK1667522T3/en active
- 2004-09-09 HU HUE04783801A patent/HUE036593T2/hu unknown
- 2004-09-09 NZ NZ545516A patent/NZ545516A/en not_active IP Right Cessation
- 2004-09-09 JP JP2006526347A patent/JP4690324B2/ja not_active Expired - Lifetime
- 2004-09-09 KR KR1020117017803A patent/KR101319388B1/ko not_active Expired - Lifetime
- 2004-09-09 ES ES04783801.6T patent/ES2662196T3/es not_active Expired - Lifetime
- 2004-09-09 PT PT172006256T patent/PT3342425T/pt unknown
- 2004-09-09 CA CA2536015A patent/CA2536015C/en not_active Expired - Lifetime
- 2004-09-09 MX MXPA06002660A patent/MXPA06002660A/es active IP Right Grant
- 2004-09-09 EP EP17200625.6A patent/EP3342425B1/en not_active Expired - Lifetime
- 2004-09-09 SI SI200432432T patent/SI1667522T1/en unknown
- 2004-09-09 HU HUE17200625A patent/HUE048359T2/hu unknown
- 2004-09-09 US US10/938,184 patent/US7494982B2/en not_active Expired - Lifetime
- 2004-09-09 ES ES17200625T patent/ES2775525T3/es not_active Expired - Lifetime
- 2004-09-09 WO PCT/US2004/029718 patent/WO2005023994A2/en not_active Ceased
- 2004-09-09 DK DK17200625.6T patent/DK3342425T3/da active
- 2004-09-09 EP EP04783801.6A patent/EP1667522B1/en not_active Expired - Lifetime
- 2004-09-09 CN CN200810098490.8A patent/CN101293908B/zh not_active Expired - Lifetime
- 2004-09-09 AU AU2004271215A patent/AU2004271215B2/en not_active Expired
- 2004-09-09 EP EP19209408.4A patent/EP3682903A1/en active Pending
- 2004-09-09 KR KR1020137007201A patent/KR101298493B1/ko not_active Expired - Lifetime
- 2004-09-09 PL PL17200625T patent/PL3342425T3/pl unknown
- 2004-09-09 BR BRPI0414222A patent/BRPI0414222B8/pt active IP Right Grant
- 2004-09-09 PT PT4783801T patent/PT1667522T/pt unknown
- 2004-09-09 KR KR1020067004864A patent/KR20060132802A/ko not_active Ceased
-
2006
- 2006-02-15 IL IL173747A patent/IL173747A/en active IP Right Grant
-
2008
- 2008-11-21 US US12/276,127 patent/US20090286853A1/en not_active Abandoned
-
2009
- 2009-10-07 AU AU2009222616A patent/AU2009222616A1/en not_active Abandoned
-
2010
- 2010-09-20 US US12/886,080 patent/US20120129918A1/en not_active Abandoned
- 2010-12-22 JP JP2010286755A patent/JP5923241B2/ja not_active Expired - Lifetime
-
2011
- 2011-12-15 JP JP2011274595A patent/JP2012085648A/ja active Pending
-
2012
- 2012-08-21 US US13/590,511 patent/US9404112B2/en not_active Expired - Lifetime
-
2014
- 2014-04-21 JP JP2014087190A patent/JP2014158490A/ja active Pending
-
2015
- 2015-05-18 US US14/714,732 patent/US9657296B2/en not_active Expired - Lifetime
- 2015-05-22 US US14/720,466 patent/US9388415B2/en not_active Expired - Lifetime
- 2015-05-22 US US14/720,467 patent/US9388416B2/en not_active Expired - Lifetime
-
2016
- 2016-01-28 JP JP2016014128A patent/JP6158966B2/ja not_active Expired - Lifetime
- 2016-06-27 US US15/194,230 patent/US10196641B2/en not_active Expired - Lifetime
- 2016-07-12 JP JP2016137263A patent/JP2016214248A/ja not_active Withdrawn
-
2018
- 2018-02-15 JP JP2018025362A patent/JP6758335B2/ja not_active Expired - Lifetime
- 2018-04-03 CY CY20181100365T patent/CY1120113T1/el unknown
-
2019
- 2019-07-17 JP JP2019131757A patent/JP2019170400A/ja not_active Withdrawn
-
2020
- 2020-02-26 CY CY20201100179T patent/CY1122704T1/el unknown
-
2021
- 2021-07-02 JP JP2021110558A patent/JP2021169466A/ja not_active Withdrawn
-
2023
- 2023-05-26 JP JP2023086871A patent/JP2023099808A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011092201A5 (https=) | ||
| JP2007504830A5 (https=) | ||
| JP2013518107A5 (https=) | ||
| JP2019536464A5 (https=) | ||
| JP2012516856A5 (https=) | ||
| Chakraborty et al. | Harnessing the physicochemical properties of DNA as a multifunctional biomaterial for biomedical and other applications | |
| JP2013510561A5 (https=) | ||
| JP2008542285A5 (https=) | ||
| EA201070030A1 (ru) | Синтез и применение антиинвертированных фосфоротиоатных аналогов кэп-структуры матричной phk | |
| RU2011150787A (ru) | КОНЪЮГАТ миРНК И СПОСОБ ЕГО ПОЛУЧЕНИЯ | |
| JP2012526548A5 (https=) | ||
| JP2012521201A5 (https=) | ||
| JP2011246469A5 (https=) | ||
| NZ588583A (en) | Novel lipid formulations for nucleic acid delivery | |
| RU2013105329A (ru) | Молекула одноцепочечной нуклеиновой кислоты для контроля экспрессии генов | |
| JP2010513363A5 (https=) | ||
| JP2009504783A5 (https=) | ||
| JP2008533007A5 (https=) | ||
| AR072858A1 (es) | Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden | |
| JP2007302689A5 (https=) | ||
| JP2015512943A5 (https=) | ||
| WO2011142798A3 (en) | Methods of preparing targeted aptamer prodrugs | |
| JP2021502346A5 (https=) | ||
| JP2008069182A5 (https=) | ||
| JP2013537404A5 (https=) |